본문 바로가기
KERD
논문KCI 등재

Update of Anticoagulation Use in Cardioembolic Stroke With a Special Reference to Endovascular Treatment

Peter Orosz|Aikaterini Theodorou|Georgios Tsivgoulis|Shadi Yaghi|Odysseas Kargiotis|Klearchos Psychogios|Thanh N. Nguyen|Lina Palaiodimou|Simona Sacco|Apostolos Safouris|George Magoufis|Theodore Karapanayiotides|Stavros Spiliopoulos|Sándor Nardai|Amrou Sarraj|Silke Walter|Guillaume Turc
대한뇌졸중학회 (The Korean Stroke Society)|2024.01|대한뇌졸중영문학회지 (Journal of stroke)|제26권 제1호|pp. 13-25

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

Ischemic strokeEndovascular treatmentHemorrhagic transformationAnticoagulationSymptomatic intracranial hemorrhage
주제분류신경과학

초록

Cardioembolic stroke is a major cause of morbidity, with a high risk of recurrence, and anticoagulation represents the mainstay of secondary stroke prevention in most patients. The implementation of endovascular treatment in routine clinical practice complicates the decision to initiate anticoagulation, especially in patients with early hemorrhagic transformation who are considered at higher risk of hematoma expansion. Late hemorrhagic transformation in the days and weeks following stroke remains a potentially serious complication for which we still do not have any established clinical or radiological prediction tools. The optimal time to initiate therapy is challenging to define since delaying effective secondary prevention treatment exposes patients to the risk of recurrent embolism. Consequently, there is clinical equipoise to define and individualize the optimal timepoint to initiate anticoagulation combining the lowest risk of hemorrhagic transformation and ischemic recurrence in cardioembolic stroke patients. In this narrative review, we will highlight and critically outline recent observational and randomized relevant evidence in different subtypes of cardioembolic stroke with a special focus on anticoagulation initiation following endovascular treatment. We will refer mainly to the commonest cause of cardioembolism, non-valvular atrial fibrillation, and examine the possible risk and benefit of anticoagulation before, during, and shortly after the acute phase of stroke. Other indications of anticoagulation after ischemic stroke will be briefly discussed. We provide a synthesis of available data to help clinicians individualize the timing of initiation of oral anticoagulation based on the presence and extent of hemorrhagic transformation as well as stroke severity.

Abstract

Cardioembolic stroke is a major cause of morbidity, with a high risk of recurrence, and anticoagulation represents the mainstay of secondary stroke prevention in most patients. The implementation of endovascular treatment in routine clinical practice complicates the decision to initiate anticoagulation, especially in patients with early hemorrhagic transformation who are considered at higher risk of hematoma expansion. Late hemorrhagic transformation in the days and weeks following stroke remains a potentially serious complication for which we still do not have any established clinical or radiological prediction tools. The optimal time to initiate therapy is challenging to define since delaying effective secondary prevention treatment exposes patients to the risk of recurrent embolism. Consequently, there is clinical equipoise to define and individualize the optimal timepoint to initiate anticoagulation combining the lowest risk of hemorrhagic transformation and ischemic recurrence in cardioembolic stroke patients. In this narrative review, we will highlight and critically outline recent observational and randomized relevant evidence in different subtypes of cardioembolic stroke with a special focus on anticoagulation initiation following endovascular treatment. We will refer mainly to the commonest cause of cardioembolism, non-valvular atrial fibrillation, and examine the possible risk and benefit of anticoagulation before, during, and shortly after the acute phase of stroke. Other indications of anticoagulation after ischemic stroke will be briefly discussed. We provide a synthesis of available data to help clinicians individualize the timing of initiation of oral anticoagulation based on the presence and extent of hemorrhagic transformation as well as stroke severity.

참고문헌 (92)

  1. Aguilar MI, "Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonvalvular atrial fibrillation and no history of stroke or transient ischemic attacks", Cochrane Database Syst Rev, 3, pp.CD006186~ (2007)
  2. Liu C, "Severe blood-brain barrier disruption in cardioembolic stroke", Front Neurol, 9, pp.55~ (2018)
  3. Kobeissi H, "Outcomes of patients with atrial fibrillation following thrombectomy for stroke : a systematic review and metaanalysis", JAMA Netw Open, 6, pp.e2249993~ (2023)
  4. Berge E, "Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation : a double-blind randomised study", Lancet, 355, pp.1205~1210 (2000)
  5. Saxena R, "Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischemic stroke and atrial fibrillation in the international stroke trial", Stroke, 32, pp.2333~2337 (2001)
  6. Fang MC, "Thirty-day mortality after ischemic stroke and intracranial hemorrhage in patients with atrial fibrillation on and off anticoagulants", Stroke, 43, pp.1795~1799 (2012)
  7. Paciaroni M, "Early hemorrhagic transformation of brain infarction : rate, predictive factors, and influence on clinical outcome : results of a prospective multicenter study", Stroke, 39, pp.2249~2256 (2008)
  8. van der Steen W, "Timing of symptomatic intracranial hemorrhage after endovascular stroke treatment", Eur Stroke J, 7, pp.393~401 (2022)
  9. Kirchhof P, "2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS", Eur J Cardiothorac Surg, 50, pp.e1~e88 (2016)
  10. Ahmed N, "Recommendations from the ESO-Karolinska Stroke Update Conference, Stockholm 13-15 November 2016", Eur Stroke J, 2, pp.95~102 (2017)
  11. Powers WJ, "Guidelines for the early management of patients with acute ischemic stroke : 2019 update to the 2018 guidelines for the early management of acute ischemic stroke : a guideline for healthcare professionals from the American Heart Association", American Stroke Association, 2019, pp.50, e344~e418
  12. Nogueira RG, "Predictors and clinical relevance of hemorrhagic transformation after endovascular therapy for anterior circulation large vessel occlusion strokes : a multicenter retrospective analysis of 1122 patients", J Neurointerv Surg, 7, pp.16~21 (2015)
  13. Hacke W, "Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke(ECASS II)", Lancet, 352, pp.1245~1251 (1998)
  14. Hacke W, "Thrombolysis with alteplase 3 to 4. 5 hours after acute ischemic stroke", N Engl J Med, 359, pp.1317~1329 (2008)
  15. Wahlgren N, "Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study(SITS-MOST) : an observational study", Lancet, 369, pp.275~282 (2007)
  16. von Kummer R, "The Heidelberg bleeding classification : classification of bleeding events after ischemic stroke and reperfusion therapy", Stroke, 46, pp.2981~2986 (2015)
  17. Paciaroni M, "Hemorrhagic transformation in patients with acute ischemic stroke and atrial fibrillation : time to initiation of oral anticoagulant therapy and outcomes", J Am Heart Assoc, 7, pp.e010133~ (2018)
  18. Tsivgoulis G, "Fatal intracranial haemorrhage occurring after oral anticoagulant treatment initiation for secondary stroke prevention in patients with atrial fibrillation", Eur J Neurol, 27, pp.1612~1617 (2020)
  19. Seiffge DJ, "Direct oral anticoagulants versus vitamin K antagonists after recent ischemic stroke in patients with atrial fibrillation", Ann Neurol, 85, pp.823~834 (2019)
  20. Yaghi S, "Anticoagulation type and early recurrence in cardioembolic stroke : the IAC study", Stroke, 51, pp.2724~2732 (2020)
  21. Hong KS, "Rivaroxaban vs warfarin sodium in the ultra-early period after atrial fibrillation–related mild ischemic stroke : a randomized clinical trial", JAMA Neurol, 74, pp.1206~1215 (2017)
  22. Palaiodimou L, "Early anticoagulation in patients with acute ischemic stroke due to atrial fibrillation : a systematic review and meta-analysis", J Clin Med, 11, pp.4981~ (2022)
  23. Polymeris AA, "Once versus twice daily direct oral anticoagulants in patients with recent stroke and atrial fibrillation", Eur Stroke J, 7, pp.221~229 (2022)
  24. Klijn CJ, "Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation : a European Stroke Organisation guideline", Eur Stroke J, 4, pp.198~223 (2019)
  25. Seiffge DJ, "Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation", Lancet Neurol, 18, pp.117~126 (2019)
  26. Malhotra K, "Non-vitamin K oral anticoagulants in stroke patients : practical issues", J Stroke, 19, pp.104~106 (2017)
  27. Paciaroni M, "Prediction of early recurrent thromboembolic event and major bleeding in patients with acute stroke and atrial fibrillation by a risk stratification schema : the ALESSA score study", Stroke, 48, pp.726~732 (2017)
  28. Yaghi S, "Ischaemic stroke on anticoagulation therapy and early recurrence in acute cardioembolic stroke : the IAC study", J Neurol Neurosurg Psychiatry, 92, pp.1062~1067 (2021)
  29. Yaghi S, "Diagnosis and management of cardioembolic stroke", Continuum(Minneap Minn), 29, pp.462~485 (2023)
  30. Kimura S, "Practical"1-2-3-4-day"rule for starting direct oral anticoagulants after ischemic stroke with atrial fibrillation : combined hospital-based cohort study", Stroke, 53, pp.1540~1549 (2022)
  31. Oldgren J, "Early versus delayed non–vitamin K antagonist oral anticoagulant therapy after acute ischemic stroke in atrial fibrillation(TIMING) : a registrybased randomized controlled noninferiority study", Circulation, 146, pp.1056~1066 (2022)
  32. Steffel J, "2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation", Europace, 23, pp.1612~1676 (2021)
  33. Connolly SJ, "Rivaroxaban in rheumatic heart disease-associated atrial fibrillation", N Engl J Med, 387, pp.978~988 (2022)
  34. Eikelboom JW, "Dabigatran versus warfarin in patients with mechanical heart valves", N Engl J Med, 369, pp.1206~1214 (2013)
  35. Fanaroff AC, "Non-vitamin K antagonist oral anticoagulants in patients with valvular heart disease", Eur Heart J Suppl, 24(Suppl A), pp.A19~A31 (2022)
  36. Jawitz OK, "Rationale and design of PROACT Xa : a randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X aortic heart valve", Am Heart J, 227, pp.91~99 (2020)
  37. "Another DOAC fails in the setting of mechanical heart valves" (2022)[URL]
  38. Otto CM, "2020 ACC", AHA guideline for the management of patients with valvular heart disease : a report of the American College of Cardiology, Circulation, pp.2021, 143[DOI]
  39. Kuramatsu JB, "Management of therapeutic anticoagulation in patients with intracerebral haemorrhage and mechanical heart valves", Eur Heart J, 39, pp.1709~1723 (2018)
  40. Kleindorfer DO, "2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack : a guideline from the American Heart Association", American Stroke Association, 2021, pp.52, e364~e467
  41. Robinson AA, "Off-label use of direct oral anticoagulants compared with warfarin for left ventricular thrombi", JAMA Cardiol, 5, pp.685~692 (2020)
  42. Huang L, "Systematic review of efficacy of direct oral anticoagulants and vitamin K antagonists in left ventricular thrombus", ESC Heart Fail, 9, pp.3519~3532 (2022)
  43. Kelly J, "Venous thromboembolism after acute stroke", Stroke, 32, pp.262~267 (2001)
  44. Aboul-Nour H, "Mechanical thrombectomy for acute ischemic stroke in metastatic cancer patients : a nationwide cross-sectional analysis", J Stroke, 25, pp.119~125 (2023)
  45. Gómez-Outes A, "Case fatality rates of recurrent thromboembolism and bleeding in patients receiving direct oral anticoagulants for the initial and extended treatment of venous thromboembolism : a systematic review", J Cardiovasc Pharmacol Ther, 20, pp.490~500 (2015)
  46. Psychogios K, "Floating carotid thrombus in a patient with essential thrombocytemia due to calreticulin mutation", Stroke, 54, pp.e207~e208 (2023)
  47. Singh RJ, "Intraluminal thrombi in the cervico-cephalic arteries", Stroke, 50, pp.357~364 (2019)
  48. Das S, "Composition, treatment, and outcomes by radiologically defined thrombus characteristics in acute ischemic stroke", Stroke, 54, pp.1685~1694 (2023)
  49. Kim JS, "Early administration of edoxaban after acute ischemic stroke in patients with nonvalvular atrial fibrillation : a pilot randomized trial", J Stroke, 25, pp.311~314 (2023)
  50. Fischer U, "Early versus later anticoagulation for stroke with atrial fibrillation", N Engl J Med, 388, pp.2411~2421 (2023)
  51. Best JG, "Optimal timing of anticoagulation after acute ischemic stroke with atrial fibrillation(OPTIMAS) : protocol for a randomized controlled trial", Int J Stroke, 17, pp.583~589 (2022)
  52. King BT, "Optimal delay time to initiate anticoagulation after ischemic stroke in atrial fibrillation(START) : methodology of a pragmatic, responseadaptive, prospective randomized clinical trial", Int J Stroke, 14, pp.977~982 (2019)
  53. Alrohimi A, "Protocol for LASER : a randomized evaluation and an associated registry of early anticoagulation with edoxaban after ischemic stroke in patients with atrial fibrillation", Front Neurol, 12, pp.645822~ (2021)
  54. Georgi B, "Leveraging human genetics to estimate clinical risk reductions achievable by inhibiting factor XI", Stroke, 50, pp.3004~3012 (2019)
  55. Shoamanesh A, "Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke(PACIFIC-stroke) : an international, randomised, double-blind, placebo-controlled, phase 2b trial", Lancet, 400, pp.997~1007 (2022)
  56. Sharma M, "Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention(AXIOMATICSSP) : a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial", Lancet Neurol, 23, pp.46~59 (2024)
  57. "OCEANIC-AF study stopped early due to lack of efficacy" (2023)[URL]
  58. Meinel TR, "Endovascular stroke treatment and risk of intracranial hemorrhage in anticoagulated patients", Stroke, 51, pp.892~898 (2020)
  59. Ramos-Araque ME, "Oral anticoagulation and risk of symptomatic hemorrhagic transformation in stroke patients treated with mechanical thrombectomy : data from the nordictus registry", Front Neurol, 11, pp.594251~ (2020)
  60. Küpper C, "Endovascular stroke treatment in orally anticoagulated patients : an analysis from the German stroke registry-endovascular treatment", J Neurol, 268, pp.1762~1769 (2021)
  61. Turc G, "European Stroke Organisation(ESO)-European Society for Minimally Invasive Neurological Therapy(ESMINT)guidelines on mechanical thrombectomy in acute ischaemic strokeendorsed by Stroke Alliance for Europe(SAFE)", Eur Stroke J, 4, pp.6~12 (2019)
  62. van de Graaf RA, "Periprocedural intravenous heparin during endovascular treatment for ischemic stroke : results from the MR CLEAN registry", Stroke, 50, pp.2147~2155 (2019)
  63. van de Graaf RA, "Periprocedural antithrombotic treatment during acute mechanical thrombectomy for ischemic stroke : a systematic review", Front Neurol, 9, pp.238~ (2018)
  64. Paciaroni M, "Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke : a meta-analysis of randomized controlled trials", Stroke, 38, pp.423~430 (2007)
  65. van der Steen W, "Safety and efficacy of aspirin, unfractionated heparin, both, or neither during endovascular stroke treatment(MR CLEAN-MED) : an open-label, multicentre, randomised controlled trial", Lancet, 399, pp.1059~1069 (2022)
  66. Altavilla R, "Anticoagulation after stroke in patients with atrial fibrillation", Stroke, 50, pp.2093~2100 (2019)
  67. Douketis JD, "Perioperative bridging anticoagulation in patients with atrial fibrillation", N Engl J Med, 373, pp.823~833 (2015)
  68. Kovacs MJ, "Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism(PERIOP2) : double blind randomised controlled trial", BMJ, 373, pp.n1205~ (2021)
  69. Yang M, "Safety and efficacy of heparinization during mechanical thrombectomy in acute ischemic stroke", Front Neurol, 10, pp.299~ (2019)
  70. Lee JS, "Endovascular treatment of large vessel occlusion strokes due to intracranial atherosclerotic disease", J Stroke, 24, pp.3~20 (2022)
  71. Liu X, "Endovascular treatment versus standard medical treatment for vertebrobasilar artery occlusion(BEST) : an open-label, randomised controlled trial", Lancet Neurol, 19, pp.115~122 (2020)
  72. Zhu X, "Safety of glycoprotein IIb-IIIa inhibitors used in stroke-related treatment : a systematic review and meta-analysis", Clin Appl Thromb Hemost, 26, pp.1076029620942594~ (2020)
  73. Xu Y, "Efficacy and safety of early anticoagulation after endovascular treatment in patients with atrial fibrillation", Stroke Vasc Neurol, 8, pp.405~412 (2023)
  74. Goyal M, "Endovascular thrombectomy after largevessel ischaemic stroke : a meta-analysis of individual patient data from five randomised trials", Lancet, 387, pp.1723~1731 (2016)
  75. Olthuis SGH, "Endovascular treatment versus no endovascular treatment after 6-24 h in patients with ischaemic stroke and collateral flow on CT angiography(MR CLEAN-LATE)in the Netherlands : a multicentre, open-label, blinded-endpoint, randomised, controlled, phase 3 trial", Lancet, 401, pp.1371~1380 (2023)
  76. Huo X, "Trial of endovascular therapy for acute ischemic stroke with large infarct", N Engl J Med, 388, pp.1272~1283 (2023)
  77. Yoshimura S, "Endovascular therapy for acute stroke with a large ischemic region", N Engl J Med, 386, pp.1303~1313 (2022)
  78. Palaiodimou L, "Endovascular treatment for acute basilar artery occlusion : a fragility index meta-analysis", J Clin Med, 12, pp.2617~ (2023)
  79. Sabben C, "Endovascular therapy or medical management alone for isolated posterior cerebral artery occlusion : a multicenter study", Stroke, 54, pp.928~937 (2023)
  80. Berberich A, "Endovascular therapy versus no endovascular therapy in patients receiving best medical management for acute isolated occlusion of the posterior cerebral artery : a systematic review and meta-analysis", Eur J Neurol, 29, pp.2664~2673 (2022)
  81. Nishimoto T, "Timing of direct oral anticoagulants for hemorrhagic transformation after endovascular treatment in acute ischemic stroke", J Stroke Cerebrovasc Dis, 31, pp.106507~ (2022)
  82. Ma H, "The optimum anticoagulation time after endovascular thrombectomy for atrial fibrillation-related large vessel occlusion stroke : a real-world study", J Neurol, 270, pp.2084~2095 (2023)
  83. Hallevi H, "Anticoagulation after cardioembolic stroke : to bridge or not to bridge?", Arch Neurol, 65, pp.1169~1173 (2008)
  84. Strbian D, "The blood-brain barrier is continuously open for several weeks following transient focal cerebral ischemia", Neuroscience, 153, pp.175~181 (2008)
  85. Jickling GC, "Hemorrhagic transformation after ischemic stroke in animals and humans", J Cereb Blood Flow Metab, 34, pp.185~199 (2014)
  86. Liu HS, "Effects of microvascular permeability changes on contrast-enhanced T1 and pharmacokinetic MR imagings after ischemia", Stroke, 44, pp.1872~1877 (2013)
  87. Elsaid N, "Radiological predictors of hemorrhagic transformation after acute ischemic stroke : an evidence-based analysis", Neuroradiol J, 33, pp.118~133 (2020)
  88. Wilson D, "Cerebral microbleeds and intracranial haemorrhage risk in patients anticoagulated for atrial fibrillation after acute ischaemic stroke or transient ischaemic attack(CROMIS-2) : a multicentre observational cohort study", Lancet Neurol, 17, pp.539~547 (2018)
  89. Martí-Fàbregas J, "MRI predicts intracranial hemorrhage in patients who receive long-term oral anticoagulation", Neurology, 92, pp.e2432~e2443 (2019)
  90. Seidel G, "Sonographic evaluation of hemorrhagic transformation and arterial recanalization in acute hemispheric ischemic stroke", Stroke, 40, pp.119~123 (2009)
  91. Bernardo-Castro S, "Pathophysiology of blood-brain barrier permeability throughout the different stages of ischemic stroke and its implication on hemorrhagic transformation and recovery", Front Neurol, 11, pp.594672~ (2020)
  92. Rust R, "Insights into the dual role of angiogenesis following stroke", J Cereb Blood Flow Metab, 40, pp.1167~1171 (2020)

관련 논문AI추천

Updates on Prevention of Cardioembolic Strokes김동억, Liping Liu, M. Edip Gurol, Mehmet Akif Topcuoglu대한뇌졸중학회 · 대한뇌졸중영문학회지2018 · 제20권 제2호Occurrence of Ischemic Stroke in Patients With Atrial Fibrillation Receiving Non-Vitamin K Oral Anticoagulants: Causes and Prevention StrategiesDong Seop Jeong, Kyoung-Min Park, Oh Young Bang대한뇌졸중학회 · 대한뇌졸중영문학회지2023 · 제25권 제2호Anticoagulation Failure in Stroke: Causes, Risk Factors, and TreatmentJong S. Kim, Youngbin Choi대한뇌졸중학회 · 대한뇌졸중영문학회지2025 · 제27권 제2호Early Anticoagulation After Large Ischemic Stroke in the Initiation of Anticoagulation After Cardioembolic Stroke StudyJayachandra Muppa, Liqi Shu, Nils Henninger, Shadi Yaghi대한신경과학회 · Journal of Clinical Neurology2025 · 제21권 제6호Non-Vitamin K Oral Anticoagulants in Stroke Patients: Practical IssuesChristoph Kleinschnitz, Hans-Christoph Diener대한뇌졸중학회 · 대한뇌졸중영문학회지2016 · 제18권 제2호Recurrent Cardioembolic Stroke Treated Successfully with Repeated Mechanical Trombectomy within the Acute Index Stroke Period이한, 김동준, 김병문, 김세훈, 김영대, 남효석, 이윤주, 허지회대한신경과학회 · Journal of Clinical Neurology2015 · 제11권 제3호

이 간행물의 다른 논문 (15건)

Cerebral Amyloid Angiopathy: An Undeniable Small Vessel DiseaseJun Liu, Dongqi Yue, Li-Tao Wang, Yi Fu, Qiong Liupp. 1-12Emerging Concept of Intracranial Arterial Diseases: The Role of High Resolution Vessel Wall MRIJae W. Song, Dong-Wan Kang, Nishita Singh, Jonguk Kim, Sung Hyun Baik, Cheolkyu Jung, Do Yeon Kim, Beom Joon Kim, 배희준pp. 26-40Mechanical Thrombectomy for In-Hospital Onset Stroke: A Comparative Systematic Review and Meta-AnalysisParya Valizadeh, Amir Hassankhani, Sherief Ghozy, Melika Amoukhteh, Payam Jannatdoust, Cem Bilgin, Ramanathan Kadirvel, David F. Kallmespp. 41-53Standard Versus Intensive Blood Pressure Control in Acute Ischemic Stroke Patients Successfully Treated With Endovascular Thrombectomy: A Systemic Review and Meta-Analysis of Randomized Controlled Trials박형종, Gwang Hyun Leem, 송태진, Minho Kim, Yun Hak Kim, Sung-Il Sohnpp. 54-63Long-Term Resveratrol Intake for Cognitive and Cerebral Blood Flow Impairment in Carotid Artery Stenosis/OcclusionHitoshi Uchiyama, Mari Iwashita, Yuji Hattori, Yoshinori Kakino, Yorito Hattori, Masafumi Ihara, Kotaro Noda, Takeshi Yoshimoto, Hidehiro Iidapp. 64-74
원문 보기